Silverarc Capital Management LLC Buys 45,406 Shares of Merus (NASDAQ:MRUS)

Silverarc Capital Management LLC boosted its position in shares of Merus (NASDAQ:MRUS - Free Report) by 7.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 680,845 shares of the biotechnology company's stock after buying an additional 45,406 shares during the quarter. Merus makes up 6.3% of Silverarc Capital Management LLC's holdings, making the stock its 2nd biggest position. Silverarc Capital Management LLC owned about 0.99% of Merus worth $28,630,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Wells Fargo & Company MN lifted its stake in shares of Merus by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after buying an additional 300 shares in the last quarter. Avior Wealth Management LLC acquired a new stake in Merus during the 4th quarter worth approximately $76,000. MML Investors Services LLC acquired a new position in Merus during the 3rd quarter worth $206,000. HighTower Advisors LLC increased its stake in shares of Merus by 10.9% during the fourth quarter. HighTower Advisors LLC now owns 8,020 shares of the biotechnology company's stock worth $337,000 after buying an additional 789 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of Merus in the 4th quarter valued at $347,000. 96.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MRUS has been the topic of several recent analyst reports. William Blair reiterated an "outperform" rating on shares of Merus in a research note on Friday, February 28th. Wells Fargo & Company assumed coverage on Merus in a research note on Friday, February 7th. They issued an "overweight" rating and a $91.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $83.00 target price on shares of Merus in a report on Wednesday, April 9th. HC Wainwright reiterated a "buy" rating and issued a $85.00 price objective on shares of Merus in a research report on Monday, March 3rd. Finally, Piper Sandler initiated coverage on shares of Merus in a report on Thursday, February 13th. They set an "overweight" rating and a $84.00 target price for the company. One equities research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $85.31.

Merus Price Performance

MRUS stock traded down $0.79 during midday trading on Friday, hitting $43.57. The stock had a trading volume of 479,065 shares, compared to its average volume of 715,979. The company's 50-day moving average price is $44.08 and its 200 day moving average price is $44.78. The firm has a market cap of $3.01 billion, a PE ratio of -11.03 and a beta of 1.02. Merus has a 12-month low of $33.19 and a 12-month high of $61.61.

Merus (NASDAQ:MRUS - Get Free Report) last released its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The firm had revenue of $9.14 million during the quarter, compared to analyst estimates of $10.57 million. As a group, sell-side analysts anticipate that Merus will post -3.85 EPS for the current year.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.